The current adjunct pharmacotherapy options for weight loss is discussed by Dr W Timothy Garvey (University of Alabama at Birmingham, Birmingham, AL, USA). Semaglutide being an example, which is approved for the treatment of type 2 diabetes.
Dr W Timothy Garvey presented an abstract entitled ‘Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity‘ was presented at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.
Questions:Â
- Beyond lifestyle interventions, what are the current adjunct pharmacotherapy options for achieving weight loss? (0:27)
- Semaglutide is approved for the treatment of type 2 diabetes – what is already known about its impact on weight loss? (1:06)
Disclosures: W Timothy Garvey is on the advisory board for Alnam, Boehringer-Ingelheim, Eli Lilly, Fractyl, JAZZ Pharmaceuticals, Novo Nordisk and Pfizer. W Timothy Garvey has received grant/research support from Eli Lilly, Epitomee, Novo Nordisk and Pfizer. All clinical trials were sponsored by the University of Alabama at Birmingham.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ADA 2022.
